MorphoSys (MOR) said early Thursday it entered into a delisting agreement following the closing of its acquisition by Novartis (NVS) in May.
The companies intend to merge MorphoSys into Novartis by "initiating a squeeze-out of MorphoSys' minority shareholders."
As of June 20, Novartis holds about 91% of MorphoSys total share capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments